Assessing the Effects of HbA1c Reduction on Alleviating Nonspecific Back Pain
CompletedNot applicableNCT06064058
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Prediabetes, characterized by elevated HbA1c levels, is a common precursor to type 2 diabetes mellitus. Recent studies have suggested a potential link between prediabetes and nonspecific back pain. This randomized controlled trial aimed to assess whether reducing HbA1c levels through lifestyle interventions and, along with the correction of vitamin D and magnesium, can alleviate nonspecific back pain in prediabetic patients.
Study details
- Official title
- Assessing the Effects of HbA1c Reduction on Alleviating Nonspecific Back Pain in Prediabetic Non-obese Patients: A Randomized Controlled Trial
- Conditions
- Interventions
- Dietary supplement: Ghazwan program
- Drug: Standard management
- Sponsor
- University of Baghdad
- Start date
- 2023-01-30
- Primary completion
- 2023-08-30
- Sex
- All
- Age range
- from 20 Years
- Results posted
- No results posted in this snapshot
- Countries
- Iraq
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Poor sleep (less than 6 hours per day) * chronic back pain * Multiple joint pain * non-specific back pain * HBA1C more than 5.7 * ability to record the data Exclusion Criteria: * Not able to record data * previous spine surgeries * severe OA in knee * Spinal stenosis * Peripheral vascular diseases * Rheumatological diseases * Lumbar disc prolapse * uncooperative patient
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06064058